ABT vs GMED · P/E 25, rev $44.33B vs P/E 42, rev $1.55B
Abbott Laboratories (ABT) versus Globus Medical (GMED) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Globus Medical (GMED) is a medical devices company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported GMED revenue for 2026-06-30 was $1.55B. Net income was $275.9M. GMED currently screens at market cap $7.66B and trailing P/E 42.1.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. GMED currently screens at market cap $7.66B and trailing P/E 42.1.
Not investment advice. Open the ABT and GMED stock pages for the full models.
Not investment advice.